PHAR - Pharming Group NV Debt to Book Capitalization Ratio
Pharming Group N.V. (PHAR) relies on the expertise of top biologists motivated by the actual saving of lives. The business model is based on patients' total dependence on exclusive medications, while profitability is limited by government oversight and stands at 0.49. The company also implements green chemistry and bioethics during drug development. This PHAR price chart clearly visualizes the market dynamics of this immune therapy manufacturer.
%20Debt%20to%20Net%20Assets%20Ratio&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_PHAR_-_Pharming-Group-N.V._-_Debt-to-Net-Assets-Ratio "Pharming Group N.V. - PHAR Debt to Book Capitalization Ratio (period 07/04/2022 - 10/27/2026) | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for Pharming Group NV (PHAR)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Summary company analytics:Pharming Group N.V. (PHAR)
This indicator determines the proportion of debt relative to equity based on book value, allowing for an assessment of actual financial leverage without the influence of market volatility. The stable current balance sheet leverage ratio confirms the ability of Pharming Group N.V. (PHAR) to finance the expansion of orphan drugs using its own resources, minimizing credit risks while scaling global sales.
Who Pharming Group N.V. competes with
Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Nektar Therapeutics NKTR|Debt to Book Value Ratio upstreambio.com (UPB)|ZBIO: Debts to Book Capitalization|Immunome Inc - Debts to Book Value|Debt to Book Capitalization Ratio Gossamer Corp|KALV - Debts to Book Capitalization Ratio|Debts to Book Capitalization Septerna Inc SEPN|pieris.com (PVLA) - Debt to Net Assets Ratio|SVRA (Savara) - Debts to Book Capitalization|Debts to Book Capitalization RIGL|AnaptysBio Corp (ANAB) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio ATXS (Astria Corp)|enGene Holdings Inc. - Debt to Book Capitalization Ratio|Debt to Book Value RAPT Therapeutics Inc. RAPT|Debts to Book Capitalization JBIO (Aerovate)|ACRS: Debts to Net Assets|Debt to Book Capitalization Ratio Kyverna|Tiziana Life Sciences, Ltd. (TLSA) - Debt to Book Value Ratio|Cabaletta Bio, Inc. - Debts to Book Capitalization|Debt to Net Assets ventyxbio.com (VTYX)|Theratechnologies (THTX) - Debt to Book Value|Debt to Net Assets Ratio Avalo Therapeutics, Inc. (AVTX)|ELDN (Eledon) - Debts to Book Capitalization|Agenus, Inc - Debt to Net Assets|Debt to Book Capitalization Ratio Climb Bio Inc (CLYM)|ZURA: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ATYR|Debts to Book Value Adagene Inc.|IMA (ImageneBio) - Debt to Book Value|Debts to Book Capitalization STTK|EQ - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio connectbiopharm.com CNTB|Debt to Book Value Immunic|Atara Biotherapeutics, Inc. - Debt to Net Assets Ratio|InflaRx GmbH (IFRX) - Debt to Book Capitalization Ratio|X4 Pharmaceuticals, Inc (XFOR) - Debt to Book Value Ratio|adicetbio.com - Debt to Book Value|Debts to Net Assets Celularity|Debt to Book Value INmune Bio|Debt to Book Capitalization Ratio Barinthus Biotherapeutics PLC (BRNS)|KZR (Kezar Life Sciences, Inc) - Debt to Book Value|Debts to Net Assets SABS (SAB Biotherapeutics Inc)|Akari Therapeutics (AKTX) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Enlivex Therapeutics Ltd ENLV|Debts to Book Capitalization Q32 Bio Corp (QTTB)|GOVX - Debt to Net Assets Ratio|EDSA: Debts to Book Capitalization|IBIO (iBio Corporation) - Debts to Book Capitalization|CARM - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio XTLB|BOLT - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio hcwbiologics.com (HCWB)|Debts to Book Capitalization Aptevo Therapeutics Inc.|Debt to Net Assets Ratio AIM ImmunoTech, Inc. AIM|Aditxt Corp - Debts to Book Capitalization|GRI: Debts to Book Capitalization|Debt to Book Capitalization Ratio XORTX Therapeutics XRTX|HIND (Vyome Holdings Inc.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio REVB|Debt to Book Value Indaptus Corp|Debts to Book Capitalization SCNI|Debts to Book Capitalization calcimedica.com CALI|Debt to Book Value Affimed N.V.|Debt to Net Assets Ratio Allakos Inc ALLK|Debts to Book Capitalization HOOK (HOOKIPA)|IGMS: Debts to Net Assets|ITOS (iTeos Therapeutics) - Debt to Book Capitalization Ratio|OCEA (oceanbiomedical.com) - Debt to Book Value|Debt to Book Capitalization Ratio TCBP|Debt to Book Value Third Harmonic Bio Inc. (THRD)